ALT Earnings Date: Nov 5, 2026 (Estimated) — Altimmune, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ALT's next earnings date?
Altimmune, Inc. (ALT) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.14 on revenue of $1,750.
How did ALT do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), Altimmune, Inc. posted EPS of -$0.12 versus the -$0.13 estimate, a beat of 7.7%. Revenue was $0 against a $1,400 estimate. The stock's 1-day post-earnings move was -2.3%.
How much does ALT stock move after earnings?
ALT beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.4% (up or down) in the day after earnings.
About Altimmune, Inc.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.13 | -0.12 | +7.69% | $0 | ✅ Beat | -2.33% | -1.00% | +9.67% |
| 2026-08-11 | -0.14 | -0.12 | +11.44% | — | ✅ Beat | -3.93% | -1.64% | +9.84% | |
| 2026-05-13 | Q1 2026 | -0.25 | -0.18 | +28.00% | $0 | ✅ Beat | -1.95% | -11.04% | -15.91% |
| 2026-03-05 | Q4 2025 | -0.25 | -0.27 | -8.00% | $26,000 | ❌ Miss | -17.92% | -11.01% | -21.78% |
| 2025-11-06 | Q3 2025 | -0.28 | -0.21 | +25.00% | $5,000 | ✅ Beat | +5.07% | +12.80% | +39.73% |
| 2025-08-12 | Q2 2025 | -0.32 | -0.27 | +15.62% | $5,000 | ✅ Beat | +7.10% | +5.33% | +8.58% |
| 2025-02-27 | Q4 2024 | -0.34 | -0.33 | +2.94% | $5,000 | ✅ Beat | +8.08% | -3.70% | -6.23% |
| 2024-11-12 | Q3 2024 | -0.35 | -0.32 | +8.57% | $5,000 | ✅ Beat | +29.12% | -2.72% | +18.91% |
Showing last 8 quarters.